Cardiff: New Lead Program in Metastatic Colorectal Cancer, Expanded Pfizer Relationship

 Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA -

 - First-line mCRC represents substantial increase in patient impact and market opportunity over second-line -

 - Pfizer Ignite will be responsible for the clinical execution of new first-line mCRC trial with interim topline data expected in mid-2024 -

 - Cash position on June 30, 2023 was $89.4 million; sufficient to fund operations into 2025 and through interim topline results from mCRC trial -

 - Company will hold a conference call today at 5:00 p.m. ET/2:00 p.m. PT -

Cardiff Oncology will host a corresponding conference call and live webcast at 5:00 p.m. ET/2:00 p.m. PT on August 7, 2023. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at www.cardiffoncology.com. A webcast replay will be available in the investor relations section on the company's website for 30 days following the completion of the call.

https://finance.yahoo.com/news/cardiff-oncology-announces-lead-program-200500856.html